Titan Pharmaceuticals Announces FDA's Acceptance of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of New Drug Application for Probuphine

SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 28, 2015) - Titan Pharmaceuticals, Inc. ( OTCQB : TTNP ) announced today that the U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for Probuphine®, a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment of opioid addiction. Probuphine was developed utilizing Titan's long-term, continuous drug delivery technology, ProNeura™. The FDA has set Feb. 27, 2016 as a target date for action on the application, which was submitted by Titan's development and commercialization partner Braeburn Pharmaceuticals.

"We are pleased that the FDA has accepted for review the resubmission of the NDA for Probuphine, and will be working with the agency and Braeburn to achieve our goal of offering the first product on the market to provide maintenance treatment of opioid addiction continuously for six months following a single treatment," said Kate Beebe, PhD, Titan's executive vice president and chief development officer.

U.S. Health and Human Services (HHS) Department Secretary Sylvia Burwell recently announced that HHS will move to expand access to medication-assisted-treatment (MAT) by revising the regulations related to the prescribing of buprenorphine to treat opioid dependence. The current cap on the number of patients that can be treated with buprenorphine products by a physician limits the availability of this important medication-assisted-therapy. The HHS revision to the regulation will be developed to provide a balance between expanding the supply of buprenorphine based treatment, encouraging use of evidence-based MAT, and minimizing the risk of drug diversion.

"Opioid addiction has become a significant health epidemic, and greater access to safe and effective treatments is essential," Titan President Sunil Bhonsle said. "As federal officials seek to find a balance between increasing access and minimizing the risk of abuse and diversion, treatment options with an implant such as Probuphine could play an expanding and crucial role in the maintenance treatment of patients."

The Probuphine NDA resubmission includes results from a Phase 3 double-blind, double-dummy clinical study. The study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints.

About Opioid Addiction According to recent estimates, there are 2.2 million people with opioid addiction in the U.S. Approximately 20 percent of this population is addicted to illicit opioids, such as heroin, and the other 80 percent to prescription opioids, such as oxycodone, hydrocodone, methadone, hydromorphone and codeine. Before the year 2000, medication-assisted therapies for opioid dependence had been sanctioned to a limited number of facilities in the U.S. The Drug Addiction Treatment Act of 2000 (DATA 2000) allowed medical office-based treatment of opioid dependence and greatly expanded patient access to medication-assisted treatments. Sales of buprenorphine drug products for treatment of opioid addiction in 2014 were approximately $1.75 billion in the United States.

About Probuphine® Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, and to promote patient compliance and retention. Buprenorphine, which is the active ingredient in multiple FDA-approved drug products for the treatment of opioid dependence, is currently available in tablet and film formulations that require self-administration by patients on a daily basis.

Probuphine was developed using ProNeura™, Titan's continuous drug delivery system that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting construct is a solid matrix that is placed subdermally, normally in the upper arm in an outpatient office procedure, and removed in a similar manner at the end of the treatment period.

The efficacy and safety of Probuphine has previously been studied in several clinical trials, including a 163-patient, placebo-controlled study over a 24-week period (published in the Journal of the American Medical Association (JAMA)), and a follow on study of 287 patients (published in the journal Addiction ).

About Titan Pharmaceuticals Titan Pharmaceuticals Inc. ( OTCQB : TTNP ), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted U.S. and Canadian commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a therapeutic agent may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com .

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT: Titan Pharmaceuticals, Inc.: Sunil Bhonsle President (650) 244-4990 Investors: Stephen Kilmer (647) 872-4849 skilmer@titanpharm.com Media: Susan Thomas (619) 540-9195 sthomas@titanpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 278

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 744

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 481

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 72

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 107

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Holiday Online Spending Driven by Mobile Shopping Trends

Updated Category News Views 145

The Rise of Mobile Shopping in the Holiday Season The 2024 holiday season has presented remarkable insights into consumer behavior, showcasing a notable 9% increase in online spending throughout the United States. This year's shopping frenzy, spanning from early November to the end of December, has seen consumers gravitate towards mobile devices for their purchases,...

Continue Reading
How Trump’s Tariffs Affect Your Daily Coffee Experience

Updated Category News Views 353

Exploring the Impact of Tariffs on Coffee Prices Recently, Sen. Elizabeth Warren (D-Mass.) criticized President Donald Trump during National Coffee Day, drawing attention to the rising costs of coffee that have resulted from his contentious tariff policies. While Trump expressed festive wishes associated with the day, Warren pointed out that these tariffs have caused...

Continue Reading
Replenish Nutrients: SRC Invests $15M, Aims for 5x Capacity

Updated Category News Views 49

Replenish Nutrients Aims to Change the Game When a $15 million investment surfaces in the world of regenerative agriculture, you know someone means business. SRC Agrominerals throwing cash at Replenish Nutrients could shake things up big time. Imagine an investment poised to bump Replenish's owned capacity by fivefold. It's not pocket change; it's laying down tracks for...

Continue Reading
Investing Opportunities Amid Securities Class Actions for 2025

Updated Category News Views 113

Understanding the Recent Class Action Lawsuits Law Offices of Howard G. Smith has alerted investors about ongoing class action lawsuits for several companies including Lantheus Holdings, Inc. (NASDAQ: LNTH), VF Corporation (NYSE: VFC), Fluor Corporation (NYSE: FLR), and Cytokinetics, Incorporated (NASDAQ: CYTK). Each case presents a unique opportunity for shareholders to...

Continue Reading
Silanes Market Projected to Reach $5.20 Billion by 2029

Updated Category News Views 77

Growth of the Silanes Market Towards 2029 The silanes market has been observed to be on a significant growth trajectory, with forecasts predicting an increase from USD 3.62 billion in 2024 to USD 5.20 billion by 2029. This remarkable rise is associated with a compound annual growth rate (CAGR) of 7.5% over the coming years. The driving force behind this expansion can be...

Continue Reading